Drug Profile
Research programme: human monoclonal antibodies - Medarex/Kyto Technology and Life Science
Latest Information Update: 25 Jul 2019
Price :
$50
*
At a glance
- Originator Medarex
- Developer Kyto Technology and Life Science
- Class Monoclonal antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 03 Apr 2003 No development reported - Preclinical for Cancer in USA (unspecified route)
- 30 Jan 2001 Preclinical development for Cancer in USA (Unknown route)